Expert Panel Offers Practical Guidelines for Optimizing Epidiolex Dosing in Rare Epilepsies

Key recommendations include individualizing starting dose and titration rate based on baseline variables and prior medication responses, differentiating Epidiolex from non-approved CBD products, managing drug-drug interactions (particularly with clobazam and valproate), and tracking maximum tolerated dose as a measure of effectiveness.

Modified Delphi consensus method. Seven epilepsy specialists completed a premeeting survey based on literature review, then discussed findings over two rounds to reach consensus on recommendation statements for Epidiolex treatment in LGS, DS, and TSC.

Despite FDA approval, confusion persists among healthcare providers, patients, and caregivers about how to dose Epidiolex optimally and how it differs from over-the-counter CBD products. These real-world practice guidelines fill a gap between clinical trial protocols and everyday clinical decision-making.

Epidiolex was the first FDA-approved cannabis-derived medication. As prescribing experience grows, real-world insights from experienced clinicians become valuable for the broader medical community, especially given the confusion between pharmaceutical CBD and unregulated CBD products that persists among both providers and patients.

Consensus-based recommendations reflect expert opinion, not randomized trial evidence for specific dosing strategies. The panel of seven experts, while experienced, represents a small group. Recommendations may not apply to patients with other types of epilepsy.